Endurant Capital Management LP Invests $1.14 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Endurant Capital Management LP bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,187 shares of the biotechnology company’s stock, valued at approximately $1,143,000. Several other large investors have […]

Related Keywords

United States ,Christopher Richard Anzalone ,Piper Sandler ,Sanfordc Bernstein ,Arrowhead Pharmaceuticals ,Nasdaq ,Alps Advisors Inc ,Quarter For Arrowhead Pharmaceuticals ,Securities Exchange Commission ,Insider Activity At Arrowhead Pharmaceuticals ,Exchange Commission ,News Ratings For Arrowhead Pharmaceuticals Daily ,Charles Schwab Investment Management Inc ,Arrowhead Pharmaceuticals Trading ,Evolutionary Tree Capital Management ,Arrowhead Pharmaceuticals Inc ,Endurant Capital Management ,Get Rating ,Tree Capital Management ,Partners Management ,Sigma Investments ,Charles Schwab Investment Management ,Schwab Investment Management ,Director Douglas ,Richard Anzalone ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,